Results 131 to 140 of about 2,912 (169)

Meropenem-Vaborbactam in the Treatment of Acute Bacterial Infections [PDF]

Journal of Clinical Medicine, 2019
This study reports the integrated analysis of two phase III studies of meropenem-vaborbactam in the treatment of acute bacterial infections. Targeting Antibiotic Non-Susceptible Gram-Negative Organisms (TANGO) I compared the clinical efficacy and tolerability of meropenem-vaborbactam and piperacillin-tazobactam in the treatment of complicated urinary ...
Chih-Cheng Lai, Hung-Jen Tang, Tang Hung-Jen   +2 more
exaly   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

In Vitro Susceptibility of Nonfermenting Gram-Negative Rods To Meropenem–Vaborbactam and Delafloxacin

Future Microbiology, 2023
Aim: Meropenem-vaborbactam and delafloxacin activities were not assessed against Achromobacter spp. (Achr), Burkholderia cepacia complex (Bcc) and Stenotrophomonas maltophilia (Smal). Methodology: A total of 106 Achr, 57 Bcc and 100 Smal were tested with gradient diffusion test of meropenem-vaborbactam, delafloxacin and comparators.
Farfour, Eric, D’epenoux, Louise Ruffier, Muggeo, Anaëlle, de Verdière, Sylvie, Alauzet, Corentine, Crémet, Lise, Moussalih, Sophie, Roux, Antoine, Vasse, Marc, Bosphore, Amélie, Corvec, Stéphane, Guillard, Thomas   +11 more
openaire   +7 more sources

Oxygenator impact on meropenem/vaborbactam in extracorporeal membrane oxygenation circuits

Perfusion, 2021
Introduction: To determine the oxygenator impact on alterations of meropenem (MEM)/vaborbactam (VBR) in a contemporary neonatal/pediatric (1/4-inch) and adolescent/adult (3/8-inch) extra corporeal membrane oxygenation (ECMO) circuit including the Quadrox-i ®
Jeffrey J Cies, Peter Nikolos, Wayne S Moore, Nadji Giliam, Tracy Low, Daniel Marino, Jillian Deacon, Adela Enache, Arun Chopra   +8 more
openaire   +2 more sources

An Update on Existing and Emerging Data for Meropenem-Vaborbactam

Clinical Therapeutics, 2020
The search for new agents to treat multidrug-resistant gram-negative bacterial infections has been ongoing. Specifically, carbapenem-resistant Enterobacteriaceae (CRE) infections often exhibit multiple resistance mechanisms, including alterations in drug structure, bacterial efflux pumps, and drug permeability.
Bethany R, Shoulders, Anthony M, Casapao, Veena, Venugopalan   +2 more
openaire   +2 more sources

An evaluation of meropenem/vaborbactam for the treatment of nosocomial pneumonia

Expert Opinion on Pharmacotherapy, 2020
Introduction: Nosocomial pneumonias are the second most common healthcare-associated infections (HCAIs), often associated with the presence of Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli, Acinetobacter species, and Enterobacter species.
Lauren M. Groft, Kimberly C. Claeys, Emily L. Heil   +2 more
openaire   +2 more sources

In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme

International Journal of Antimicrobial Agents, 2018
The activity of meropenem/vaborbactam was evaluated against 11 559 Enterobacteriaceae isolates, including 330 carbapenem-resistant phenotypes (CRE) and carbapenemase genotypes collected worldwide during 2015. Antimicrobial susceptibility testing for meropenem/vaborbactam (inhibitor at 8 mg/L) and comparators was performed by the reference broth ...
Rodrigo Mendes, Michael Huband, Mariana Castanheira   +2 more
exaly   +3 more sources

Meropenem/Vaborbactam, the First Carbapenem/β-Lactamase Inhibitor Combination

Annals of Pharmacotherapy, 2018
Objective: To review the pharmacology, spectrum of activity, pharmacokinetics, pharmacodynamics, safety, efficacy, administration, and considerations for clinical use of meropenem/vaborbactam (M/V). Data Sources: A literature search using PubMed and clinicaltrials.gov (June 2013 to December 2017) was conducted using the search terms meropenem ...
Jonathan C, Cho, Monika T, Zmarlicka, Kristy M, Shaeer, Joe, Pardo   +3 more
openaire   +2 more sources

A Brief Review of a New Antibiotic: Meropenem-vaborbactam

The Senior Care Pharmacist, 2019
Meropenem-vaborbactam is a newly approved antibiotic for complex urinary tract infections and to treat carbapenem-resistant Enterobacteriaceae infections. Its advantage over meropenem is the betalactamase inhibitor which slows bacterial resistance. This medication has been studied in numerous countries and has relatively few side effects.
openaire   +2 more sources

Meropenem/vaborbactam

Reactions Weekly, 2021
openaire   +2 more sources

Meropenem/vaborbactam fixed combination for the treatment of patients with complicated urinary tract infections

Drugs of Today, 2017
On August 29, 2017, the United States Food and Drug Administration (FDA) approved meropenem/ vaborbactam fixed combination for the treatment of adults with complicated urinary tract infections (cUTI). The decision was based on substantial preclinical and clinical data, including two recent trials involving hundreds of adults with cUTI.
M W, McCarthy, T J, Walsh
openaire   +2 more sources